Pyelonephritis nursing: CVA tenderness, urosepsis risk, and IV antibiotic therapy

Pyelonephritis is a bacterial infection of the kidney parenchyma and renal pelvis. It represents the ascent of lower urinary tract infection – most commonly from the bladder – into the upper urinary tract, triggering an inflammatory response that can range from a straightforward outpatient illness to a life-threatening emergency. When untreated or inadequately managed, pyelonephritis can progress to urosepsis. Most patients with urosepsis survive (30-day mortality was 2.8% in the prospective SERPENS cohort), but the risk climbs steeply once organ dysfunction or septic shock develops.

Nurses encounter pyelonephritis across med-surg, ED, and critical care settings. Understanding the pathophysiology, recognizing the classic presentation, and knowing when to escalate are core competencies – and frequent NCLEX topics. This reference covers everything from admission assessment to urosepsis recognition to patient education.

Quick reference:

Pathophysiology

Pyelonephritis develops when bacteria ascend from the lower urinary tract into the kidneys. The route is: urethra → bladder (cystitis) → ureter → renal pelvis → renal parenchyma. In most cases, the same bacteria causing a bladder infection spread upward – either due to vesicoureteral reflux, urinary obstruction, or factors that allow bacteria to adhere to and migrate along the urothelium.

Once bacteria reach the renal pelvis, they adhere to the epithelial cells of the tubules and collecting ducts. The host mounts an inflammatory response: neutrophils are recruited, causing localized pyuria (pus in the urine), and the infected tissue becomes edematous and inflamed. In uncomplicated cases, this response is contained within the kidney. In severe cases – particularly with obstruction, immunosuppression, or virulent organisms – bacteria enter the bloodstream (bacteremia), triggering the systemic inflammatory cascade of sepsis.

Why bacteria reach the kidney:

E. coli accounts for approximately 80% of community-acquired pyelonephritis. Other organisms include Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa (more common in hospital-acquired cases), Enterococcus faecalis, and Staphylococcus saprophyticus (common in young sexually active women). In diabetic or immunocompromised patients, Candida spp. must also be considered.

Signs and symptoms

The classic triad of acute pyelonephritis is fever and chills, flank pain, and lower urinary tract symptoms (dysuria, urinary frequency, urgency). However, not all three components need to be present to make the diagnosis, and severity varies widely.

Classic presentation:

• Fever (typically ≥38°C / 100.4°F) with rigors – the fever of pyelonephritis tends to be higher and more sustained than in lower UTI
• Flank pain – unilateral or bilateral, ranging from dull ache to severe pain; located at the costovertebral angle (the junction of the lower rib cage and lumbar spine)
• Costovertebral angle (CVA) tenderness – pain elicited by firm percussion at the CVA with the patient sitting or lying prone; positive CVA tenderness is the hallmark physical exam finding
• Dysuria, urgency, frequency – indicating concurrent or preceding lower UTI
• Nausea and vomiting – common; may lead to dehydration requiring IV fluid resuscitation
• Malaise, myalgia, headache – systemic inflammatory symptoms

Acute vs. chronic presentation:

In elderly patients: Classic symptoms may be absent. Altered mental status, falls, generalized weakness, anorexia, or new incontinence may be the only presenting features. A high index of suspicion is required – always consider urinary source in elderly patients with unexplained fever or new confusion.

In pregnant patients: More common (up to 2% of all pregnancies), more likely to require hospitalization, and more likely to progress to preterm labor or sepsis. Pyelonephritis in pregnancy is always treated with hospitalization and IV antibiotics.

Diagnostic findings

Diagnosis is based on clinical presentation supported by urine analysis, urine culture, and laboratory findings. Imaging is not required in straightforward cases but should be obtained when symptoms are severe, the patient does not improve within 48–72 hours, or complications are suspected.

Urinalysis findings

WBC casts are the key differentiator: their presence on urinalysis confirms renal parenchymal involvement rather than bladder-only infection. Reference the full lab values cheat sheet for normal urinalysis parameters.

Blood and urine cultures

• Urine culture with sensitivity is essential – it confirms the organism and guides antibiotic selection. Collect before starting antibiotics whenever clinically possible.
• Blood cultures (two sets from two different sites) are drawn before antibiotics whenever sepsis is suspected, and are also useful when the diagnosis is uncertain, the patient is immunocompromised, or there is no response after 48–72 hours. Many hospitals draw them on every admission for pyelonephritis. Blood cultures are positive in roughly 10–40% of patients with acute pyelonephritis, with the rate varying by severity and population, but bacteremia on its own rarely changes the antibiotic plan (Herness 2020). Bacteremia is not the same as sepsis: under Sepsis-3, urosepsis means infection plus acute organ dysfunction.

Complete blood count and metabolic panel

Imaging

CT abdomen/pelvis (with or without contrast) is the imaging study of choice when complications are suspected. It identifies renal abscess, emphysematous pyelonephritis, obstructive cause, and extent of infection. Indications: failure to improve at 48–72 hours, suspected abscess, urosepsis, or unusual presentation.

Renal ultrasound is appropriate when CT is not feasible (pregnancy, contrast allergy, radiation concern). Ultrasound can identify hydronephrosis (obstruction), abscess, and gross structural changes but is less sensitive than CT for subtle findings.

Nursing assessment

Admission assessment priorities

A systematic admission assessment should establish baseline clinical status and identify early warning signs of deterioration toward urosepsis.

Vital signs: Obtain a full set immediately. Fever ≥38°C confirms infection; tachycardia (HR >90) and hypotension (SBP <100) may indicate early sepsis. Track vital sign trends – a worsening trend over 1–2 hours requires escalation. Reference vital signs by age for normal parameters.

CVA tenderness: With the patient sitting upright, place one hand over the CVA (lower back at the junction of the 12th rib and lumbar spine) and firmly strike it with the other fist. Tenderness on percussion confirms upper tract involvement. Assess bilaterally – bilateral tenderness indicates bilateral kidney infection.

Urinary symptoms: Ask specifically about dysuria, frequency, urgency, hematuria, and changes in urine appearance. Document duration of symptoms – when did lower UTI symptoms begin? Symptoms preceding current presentation suggest ascending infection.

Hydration and volume status: Pyelonephritis combined with nausea and vomiting frequently causes dehydration. Assess skin turgor, mucous membranes, and orthostatic vital signs. Check the most recent urine output – oliguria (output <0.5 mL/kg/hr) in the context of pyelonephritis suggests AKI, obstruction, or early sepsis.

Mental status: Any change from baseline – confusion, lethargy, agitation – in the context of suspected pyelonephritis is a red flag for urosepsis until proven otherwise. Altered mental status is one of the three qSOFA criteria (see Urosepsis section below).

Pain assessment: Document location, character, severity (0–10), and radiation. Pyelonephritis pain is typically constant rather than colicky (which suggests an obstructing stone). Severe unrelenting pain in the presence of fever warrants imaging to rule out obstruction or abscess.

Ongoing monitoring: Vital signs every 4 hours (or more frequently if deteriorating), strict intake and output, daily weights, reassessment of CVA tenderness with treatment response, and trending of laboratory values.

Nursing interventions

Intervention summary

Antibiotics

Antibiotic selection depends on severity of illness, local resistance patterns, and culture results. Empiric therapy is started immediately – do not wait for culture results in a symptomatic patient.

Outpatient (mild-moderate, able to take oral medication):

• Fluoroquinolone (ciprofloxacin, levofloxacin) – the 2011 IDSA guideline made this first-line where community resistance is ≤10%. The 2025 IDSA complicated UTI guideline, which covers acute pyelonephritis, suggests avoiding a fluoroquinolone if the patient has taken one in the past 12 months
• Trimethoprim-sulfamethoxazole (TMP-SMX) – if the organism is susceptible or local resistance allows
• Oral cephalosporins (cefpodoxime, cefadroxil) – for patients unable to take fluoroquinolones or TMP-SMX

Duration: for a patient who is improving on effective therapy, the 2025 IDSA guideline suggests 5–7 days of a fluoroquinolone or 7 days of a non-fluoroquinolone agent, rather than the older 10–14 day courses. IV and oral days count toward the total.

Inpatient (severe, sepsis, pregnancy, immunocompromised):

• Ceftriaxone IV – preferred initial choice for hospitalized patients without prior ESBL history
• Piperacillin-tazobactam IV – broader coverage; used when resistant organisms suspected or prior healthcare exposure
• Fluoroquinolones IV – acceptable alternative in non-pregnant adults
• Carbapenems (meropenem, ertapenem) – reserved for ESBL-producing organisms or critically ill patients
• Step-down to oral therapy once the patient is clinically improving, able to take oral medication, and an effective oral option exists (IDSA 2025) – often at 24–48 hours; bacteremia from a urinary source does not by itself rule out an oral switch

Pregnant patients: Ceftriaxone IV is the preferred agent. Fluoroquinolones are avoided in pregnancy, TMP-SMX is avoided in the first trimester and near term, and nitrofurantoin is not used for pyelonephritis because it does not reach therapeutic levels in kidney tissue.

Fluid management

Most hospitalized patients with pyelonephritis are volume-depleted from fever and vomiting. Isotonic crystalloids (normal saline or lactated Ringer’s) are the standard initial resuscitation fluid.

• Goal urine output: 0.5–1 mL/kg/hr
• Monitor for adequate response: improved vital signs, improved urine output, resolution of dry mucous membranes
• In urosepsis with hypotension or hypoperfusion: at least 30 mL/kg IV crystalloid within the first 3 hours, starting immediately, with a balanced crystalloid such as lactated Ringer’s suggested over 0.9% saline (Surviving Sepsis Campaign 2026, Recs 10 and 44)
• Avoid excessive fluid administration in patients with known heart failure or AKI – balance resuscitation against fluid overload risk

Pain and fever management

• Acetaminophen is the safest analgesic for pyelonephritis – effective for both pain and fever without renal concerns
• NSAIDs (ibuprofen, ketorolac) may be used for pain if renal function is normal but should be withheld if creatinine is elevated, oliguria is present, or the patient is volume-depleted – NSAIDs reduce prostaglandin-mediated renal perfusion and can precipitate AKI
• Opioid analgesics are reserved for severe pain not controlled with first-line agents
• Warm compresses or heating pads to the flank provide adjunctive comfort
• Antipyretics reduce discomfort from fever and decrease insensible fluid losses

Patient education

• Complete the full antibiotic course – stopping early when symptoms improve allows resistant organisms to persist and causes recurrent infection
• Hydrate well – 2–3 liters of fluid daily unless restricted; adequate urine output flushes bacteria from the urinary tract
• Void frequently – do not hold urine for long periods; stasis promotes bacterial growth
• Wipe front to back (for women) – reduces fecal bacterial contamination of the urethra
• Return immediately if fever returns, pain worsens, or urine output decreases – these signs may indicate treatment failure or complication
• Follow-up urine culture: not needed routinely once symptoms resolve in non-pregnant adults, because IDSA advises against screening for and treating asymptomatic bacteriuria in this group (Nicolle 2019). Pregnancy is the exception: bacteriuria in pregnancy is screened for and treated, so expect repeat urine cultures for the rest of the pregnancy
• For patients with recurrent episodes: discuss risk factors, preventive strategies, and whether prophylactic antibiotics are indicated

Urosepsis

Urosepsis is sepsis originating from the urogenital tract, and it is the most feared complication of pyelonephritis. When pyelonephritis is inadequately treated or occurs in the context of obstruction, immunosuppression, or a virulent organism, the local renal infection overwhelms systemic defenses – bacteria and their endotoxins enter the bloodstream, triggering the dysregulated inflammatory response of sepsis.

Mortality depends heavily on how far that process has advanced. In the prospective SERPENS cohort (354 adults with urosepsis), 30-day mortality was 2.8% overall, and every patient who died already had a SOFA score of 2 or more at diagnosis – the Sepsis-3 marker of organ dysfunction. Comorbidity, obstruction as the cause, multidrug-resistant organisms, and respiratory failure at presentation all predicted a worse outcome. Septic shock is a different order of risk: across all infection sources, the Sepsis-3 definition of shock identified patients with hospital mortality above 40%. The clinical implication for the nurse is the same either way: the outcome turns on how early the deterioration is caught, which is why the screening below matters more than any single mortality statistic.

When to suspect urosepsis

Screen with your hospital’s sepsis tool. The Surviving Sepsis Campaign (2021, and again in 2026) recommends NEWS, NEWS2, MEWS, or SIRS over qSOFA as a single screening tool, because qSOFA misses too many early cases. qSOFA still has value as a bedside prognostic flag: a score of ≥2 in a patient with suspected infection signals high risk of poor outcomes:

qSOFA ≥2 in a patient with pyelonephritis = activate the sepsis protocol immediately. A qSOFA below 2 does not rule sepsis out; act on a positive screen from the hospital tool or on any of the warning signs below.

Additional warning signs:

• Temperature >38.3°C or <36°C (hypothermia in sepsis is an ominous sign)
• Heart rate >90 bpm
• Lactate ≥2 mmol/L (tissue hypoperfusion marker)
• Urine output <0.5 mL/kg/hr for ≥2 consecutive hours
• New confusion, agitation, or somnolence

Escalation protocol

When urosepsis is suspected:

1. Notify the provider immediately – state vitals, mental status, and urosepsis concern using SBAR
2. Obtain blood cultures × 2 (before antibiotics if possible – do not delay antibiotics >1 hour to obtain cultures)
3. Initiate broad-spectrum IV antibiotics within 1 hour for probable sepsis or any suspected shock (within 3 hours if sepsis is only possible and there is no shock, per SSC 2026). In septic shock, each hour of delay after hypotension began was associated with an average 7.6% drop in survival in a landmark retrospective study (Kumar 2006)
4. IV fluid resuscitation – at least 30 mL/kg crystalloid within 3 hours for hypotension or hypoperfusion
5. Measure serum lactate – elevated lactate (≥2 mmol/L) confirms tissue hypoperfusion
6. Continuous vital sign monitoring – consider ICU/step-down transfer
7. Vasopressors (norepinephrine, first-line) if MAP stays below 65 mmHg despite fluid resuscitation; they can be started through a well-functioning peripheral IV rather than waiting for a central line. SSC 2026 targets an initial MAP of 65 mmHg, or 60–65 mmHg in patients aged 65 and older
8. Urgent imaging (CT abdomen/pelvis) to identify obstructing cause – obstructed infected kidney requires emergent urologic decompression (ureteral stent or percutaneous nephrostomy)

See the full sepsis nursing reference for complete sepsis bundle management.

The critical teaching point: pyelonephritis + obstruction is a urologic emergency. Infected urine trapped above an obstruction (pyonephrosis) cannot be cleared by antibiotics alone – the obstruction must be relieved by urology. If a patient with pyelonephritis and fever does not improve within 48–72 hours of appropriate antibiotics, suspect obstruction and order imaging.

Complications

Urosepsis and septic shock

As described above – the most life-threatening complication. Most patients with urosepsis survive, but the risk rises steeply once organ dysfunction appears and exceeds 40% in septic shock (all sources, Sepsis-3). Early antibiotic initiation, sepsis protocol activation, and relief of any obstruction are the keys to survival.

Renal abscess and perinephric abscess

A collection of pus within the renal parenchyma (intrarenal abscess) or in the perirenal fat surrounding the kidney (perinephric abscess). Suspect if the patient fails to defervesce after 48–72 hours of appropriate antibiotics. Requires CT confirmation and usually drainage (percutaneous or surgical) in addition to prolonged antibiotics.

Emphysematous pyelonephritis

A rare but life-threatening necrotizing infection in which gas-forming bacteria (usually E. coli) produce gas within the renal parenchyma. About 96% of patients in a systematic review had diabetes. In that review, mortality was 50% with antibiotics alone, 25% with antibiotics plus emergency nephrectomy, and 13.5% with antibiotics plus percutaneous drainage, so percutaneous drainage is now part of initial management, with nephrectomy kept for patients who do not respond (Somani 2008).

Chronic pyelonephritis and renal scarring

Recurrent or poorly treated episodes of pyelonephritis cause progressive cortical scarring. The affected kidney shrinks, cortical tissue is replaced by fibrous scar, and tubular function deteriorates. Over years, this leads to chronic kidney disease and hypertension (from RAAS activation in the scarred kidney). Children with vesicoureteral reflux and recurrent pyelonephritis are at particular risk.

Acute kidney injury

Severe pyelonephritis – especially with obstruction, septic emboli, or hypoperfusion – can cause AKI through multiple mechanisms: tubular ischemia from sepsis-related hypoperfusion, direct bacterial tubular injury, and post-obstructive damage. Monitor creatinine and urine output closely throughout admission.

NCLEX-style practice questions

Question 1

A nurse is assessing a patient admitted with suspected pyelonephritis. Which physical examination technique is most specific for confirming upper urinary tract involvement?

A. Palpation of the suprapubic area for bladder distension B. Deep palpation of the left lower quadrant for rebound tenderness C. Percussion of the costovertebral angle for tenderness D. Auscultation of the renal arteries for bruits

Answer: C

Rationale: Costovertebral angle (CVA) tenderness – elicited by firm percussion at the junction of the 12th rib and lumbar spine – is the hallmark physical examination finding for upper urinary tract involvement. Positive CVA tenderness distinguishes pyelonephritis (upper tract) from cystitis (lower tract). Suprapubic tenderness indicates bladder involvement only. Rebound tenderness suggests peritoneal pathology. Renal artery bruits assess for renovascular disease.

Question 2

A patient with pyelonephritis has the following vital signs: temperature 39.1°C, HR 112 bpm, RR 24 breaths/min, BP 94/58 mmHg, and new confusion. What is the nurse’s priority action?

A. Obtain a urine specimen for culture and sensitivity B. Apply a cool compress to the forehead for fever management C. Activate the sepsis protocol and notify the provider immediately D. Administer the scheduled oral antibiotic dose

Answer: C

Rationale: This patient scores 3/3 on qSOFA: altered mental status (+1), RR ≥22 (+1), and SBP ≤100 (+1). qSOFA is a prognostic flag rather than a stand-alone screen, but a maximum score with a known infection marks very high risk. In the context of a known infection source (pyelonephritis), this presentation is urosepsis until proven otherwise. The nurse’s priority is to activate the sepsis protocol and notify the provider immediately. Blood cultures should be drawn before antibiotics if possible, but antibiotic initiation must not be delayed beyond 1 hour – in septic shock, each hour of delay was associated with roughly 7.6% lower survival (Kumar 2006). Applying a cool compress is a comfort measure that does not address the life-threatening emergency.

Question 3

A nurse is preparing to administer the first dose of ciprofloxacin to a patient with pyelonephritis. Which action is most important before administration?

A. Ensure the patient has taken a full glass of water B. Confirm that blood and urine cultures have been collected C. Verify that the patient has no penicillin allergy D. Check the patient’s most recent serum potassium level

Answer: B

Rationale: Blood and urine cultures must be collected before the first antibiotic dose whenever possible. Once antibiotics are administered, organisms begin to die and culture yield drops significantly – a sterilized culture provides no information about the causative organism or its antibiotic sensitivities. This prevents targeted de-escalation and appropriate antibiotic stewardship. Ciprofloxacin is a fluoroquinolone (not a beta-lactam), so penicillin allergy is not relevant. While hydration is important, it is not the priority action before antibiotic administration. Potassium monitoring is part of ongoing care, not a pre-administration check specific to ciprofloxacin.

Question 4

A 28-year-old pregnant patient at 22 weeks gestation is admitted with acute pyelonephritis, fever, and vomiting. Which antibiotic would the nurse expect to be ordered?

A. Ciprofloxacin IV B. Trimethoprim-sulfamethoxazole (TMP-SMX) C. Ceftriaxone IV D. Nitrofurantoin

Answer: C

Rationale: Ceftriaxone IV is the preferred antibiotic for pyelonephritis in pregnancy. Fluoroquinolones (option A) are avoided in pregnancy due to risk of fetal cartilage damage. TMP-SMX (option B) is avoided particularly in the first trimester (folate antagonism) and near term (neonatal jaundice risk). Nitrofurantoin (option D) is appropriate for lower UTI but is not indicated for pyelonephritis (upper tract infection) and is contraindicated at term. Pyelonephritis in pregnancy always warrants hospitalization and IV antibiotic therapy regardless of disease severity.

Question 5

A patient with pyelonephritis has been receiving IV ceftriaxone for 36 hours. She is now afebrile, her HR is 82 bpm, and she is tolerating oral fluids. Urine culture results show E. coli sensitive to ciprofloxacin. What would the nurse anticipate the provider ordering?

A. Continue IV ceftriaxone for a total of 14 days B. Add metronidazole IV for anaerobic coverage C. Transition to oral ciprofloxacin and prepare for discharge D. Repeat blood cultures before considering any change to therapy

Answer: C

Rationale: Step-down from IV to oral therapy is appropriate when the patient is clinically improving: afebrile, hemodynamically stable, and tolerating oral intake. The culture and sensitivity result confirms E. coli sensitivity to ciprofloxacin, making oral fluoroquinolone therapy appropriate. For a patient who is improving, the 2025 IDSA guideline suggests 5–7 days of a fluoroquinolone in total, counting both IV and oral portions (7 days was non-inferior to 14 in the Sandberg trial). Continuing IV antibiotics for 14 days is unnecessarily prolonged once oral step-down criteria are met. Adding metronidazole is not indicated – anaerobic coverage is not required for standard pyelonephritis caused by gram-negative enteric organisms.

Question 6

A nurse is educating a patient being discharged after hospitalization for pyelonephritis. Which instruction is most important to include?

A. “You can stop the antibiotic once your fever is gone for 24 hours.” B. “Reduce your fluid intake to prevent urinary urgency.” C. “Complete the full antibiotic course and come back right away if the fever or flank pain returns.” D. “Avoid all NSAIDs permanently because of the kidney damage from your infection.”

Answer: C

Rationale: Completing the prescribed course is essential – stopping early when symptoms resolve risks relapse and resistance, and returning fever or flank pain signals treatment failure that needs re-evaluation. A routine repeat urine culture is not needed in a non-pregnant adult whose symptoms have resolved (IDSA asymptomatic bacteriuria guideline). Reducing fluid intake (option B) is incorrect – adequate hydration is protective and helps clear bacteria from the urinary tract; the goal is 2–3 liters daily. Option A is dangerous – symptom resolution does not mean bacteriological cure. Option D is overly restrictive – NSAIDs can be used once renal function returns to baseline, but should be avoided during the acute infection if AKI is suspected.

Related pages

• Hydronephrosis nursing – pyelonephritis as a complication of obstructed hydronephrosis
• AKI nursing reference – acute kidney injury as a complication of severe pyelonephritis
• Sepsis nursing reference – full sepsis bundle management for urosepsis
• CKD and ESRD nursing – chronic kidney disease from recurrent pyelonephritis
• Nursing lab values cheat sheet – urinalysis and serum values reference
• Head-to-toe assessment – systematic assessment framework

This reference was written for nursing students preparing for clinical practice and NCLEX. Clinical decisions must always be made in conjunction with current institutional protocols, provider orders, and individualized patient assessment.

Author: Lindsay Smith, AGPCNP

References

1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl 1A):5S–13S.
2. Hooton TM, Stapleton AE, Roberts PL, et al. Perineal anatomy and urine-voiding characteristics of young women with and without recurrent urinary tract infections. Clin Infect Dis. 1999;29(6):1600–1601.
3. Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011;84(7):771–776.
4. Johnson JR, Russo TA. Acute pyelonephritis in adults. N Engl J Med. 2018;378(1):48–59.
5. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women. Clin Infect Dis. 2011;52(5):e103–e120. (Pyelonephritis treatment duration updated by the 2025 IDSA complicated UTI guideline, references 19–20.)
6. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 8th ed. Elsevier; 2015:886–913.
7. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810.
8. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377. (Superseded by the 2021 edition and then the 2026 edition, reference 17.)
9. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):762–774.
10. Wing DA, Fassett MJ, Getahun D. Acute pyelonephritis in pregnancy: an 18-year retrospective analysis. Am J Obstet Gynecol. 2014;210(3):219.e1–219.e6.
11. Nicolle LE. Urinary tract infections in special populations: diabetes, renal transplant, HIV infection, and spinal cord injury. Infect Dis Clin North Am. 2014;28(1):91–104.
12. Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012;380(9840):484–490.
13. Stamm WE, McKevitt M, Roberts PL, White NJ. Natural history of recurrent urinary tract infections in women. Rev Infect Dis. 1991;13(1):77–84.
14. Wagenlehner FME, Lichtenstern C, Rolfes C, et al. Diagnosis and management for urosepsis. Int J Urol. 2013;20(10):963–970. doi:10.1111/iju.12200
15. Tandogdu Z, Koves B, Ristovski S, et al. Urosepsis 30-day mortality, morbidity, and their risk factors: SERPENS study, a prospective, observational multi-center study. World J Urol. 2024;42(1):314. doi:10.1007/s00345-024-04979-2
16. Bonkat G, Bartoletti R, Bruyère F, et al. EAU Guidelines on Urological Infections. Arnhem, The Netherlands: European Association of Urology; 2024.
17. Prescott HC, Antonelli M, Alhazzani W, Møller MH, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026. Intensive Care Med. 2026;52(5):863–936. doi:10.1007/s00134-026-08361-1. Co-published in Crit Care Med. 2026;54(4):725–812. doi:10.1097/CCM.0000000000007075
18. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–1596. doi:10.1097/01.CCM.0000217961.75225.E9
19. Trautner BW, Cortés-Penfield NW, Gupta K, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2025 guideline on management and treatment of complicated urinary tract infections – selection of antibiotic therapy. Clin Infect Dis. 2025;82(Suppl 3):i36–i67. doi:10.1093/cid/ciaf460
20. Trautner BW, Cortés-Penfield NW, Gupta K, et al. Clinical practice guidelines by IDSA: 2025 guidelines on management and treatment of complicated urinary tract infections – duration of antibiotics for complicated UTI. Clin Infect Dis. 2025;82(Suppl 3):i79–i88. doi:10.1093/cid/ciaf462
21. Herness J, Buttolph A, Hammer NC. Acute pyelonephritis in adults: rapid evidence review. Am Fam Physician. 2020;102(3):173–180. PMID 32735433
22. Somani BK, Nabi G, Thorpe P, et al. Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review. J Urol. 2008;179(5):1844–1849. doi:10.1016/j.juro.2008.01.019
23. Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83–e110. doi:10.1093/cid/ciy1121